e19021 Background: Hypereosinophilic syndrome (HES) is a rare disease defined by organ damage directly attributable to hypereosinophilia of any type. The most commonly involved organ is the lung, followed by the skin. Methods: We report a single-center cohort of patients with NHL (DLBCL). Of these patients, nine had been treated with RCHOP on standard reatment protocol (6 cycle chemotherapy). In a retrospective analysis, data on treatment response, frequency of relapses, adverse events reconstitution were evaluated. Heamotology and biochemistry tests abs analysis were performed after every cycle. Results: All patients had high disease activity before RTX treatment. We found 3 patients who developed severe drug-induced hypereosinophilia with gastrointestinal involvement as a consequence of RCHOP infusion. For the case 1 Full blood count revealed a new mild eosinophilia with eosinophil count of 1 9 109 /l. After the third infusion, the eosinophil count had risen to 7.0 9 109 /L. In case 2, after the 6th infusion, the eosinophil count had risen to 6.4 9 109/L. In case 3 also it occurred in follow up period after 6th infusion and 6.8 9 109 /L. However the finding was not associated with any severe toxicity or other malignancy. No alarming feature was also notice alongside this abnormality Conclusions: Preemptive retreatment with RTX, combined with CHOP, resulted in a sustained treatment response. Hence clinical significant is not clear this stage. Strict post marketing vigilance for evaluating the use of RCHOP was warranted.